Vascular Endothelial Growth Factor A
"Vascular Endothelial Growth Factor A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced.
Descriptor ID |
D042461
|
MeSH Number(s) |
D12.644.276.100.800.200 D12.776.467.100.800.200 D23.529.100.800.200
|
Concept/Terms |
Vascular Endothelial Growth Factor A- Vascular Endothelial Growth Factor A
- Vascular Endothelial Growth Factor-A
- VEGF-A
- Vasculotropin
- VEGF
- Vascular Endothelial Growth Factor
- Vascular Permeability Factor
- Permeability Factor, Vascular
|
Below are MeSH descriptors whose meaning is more general than "Vascular Endothelial Growth Factor A".
Below are MeSH descriptors whose meaning is more specific than "Vascular Endothelial Growth Factor A".
This graph shows the total number of publications written about "Vascular Endothelial Growth Factor A" by people in this website by year, and whether "Vascular Endothelial Growth Factor A" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 2 | 2 |
1995 | 0 | 4 | 4 |
1996 | 0 | 3 | 3 |
1997 | 0 | 1 | 1 |
1998 | 0 | 1 | 1 |
1999 | 0 | 5 | 5 |
2000 | 0 | 5 | 5 |
2001 | 0 | 7 | 7 |
2002 | 0 | 9 | 9 |
2003 | 4 | 6 | 10 |
2004 | 5 | 10 | 15 |
2005 | 5 | 9 | 14 |
2006 | 2 | 9 | 11 |
2007 | 5 | 12 | 17 |
2008 | 8 | 13 | 21 |
2009 | 12 | 8 | 20 |
2010 | 6 | 13 | 19 |
2011 | 9 | 5 | 14 |
2012 | 5 | 11 | 16 |
2013 | 7 | 14 | 21 |
2014 | 3 | 12 | 15 |
2015 | 3 | 9 | 12 |
2016 | 4 | 7 | 11 |
2017 | 1 | 4 | 5 |
2018 | 3 | 6 | 9 |
2019 | 3 | 5 | 8 |
2020 | 3 | 5 | 8 |
2021 | 2 | 5 | 7 |
2022 | 2 | 5 | 7 |
2023 | 0 | 8 | 8 |
2024 | 3 | 5 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vascular Endothelial Growth Factor A" by people in Profiles.
-
Angiopoietin 1 Attenuates Dysregulated Angiogenesis in the Gastrocnemius of DMD Mice. Int J Mol Sci. 2024 Nov 04; 25(21).
-
Bevacizumab for Retinopathy of Prematurity Is Not Associated With Systemic Hypertension. J Pediatr Ophthalmol Strabismus. 2024 Nov-Dec; 61(6):434-441.
-
Anti-VEGF Pharmaceutical Prior Authorization in Retina Practices. JAMA Ophthalmol. 2024 Aug 01; 142(8):716-721.
-
The VEGF-Hypoxia Signature Is Upregulated in Basal-like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast Cancer. Clin Cancer Res. 2024 Jun 03; 30(11):2609-2618.
-
Clinical utility of angiogenic biomarkers. Am J Obstet Gynecol. 2024 06; 230(6):e124.
-
Tumor Explants Elucidate a Cascade of Paracrine SHH, WNT, and VEGF Signals Driving Pancreatic Cancer Angiosuppression. Cancer Discov. 2024 Feb 08; 14(2):348-361.
-
ASSOCIATION OF METFORMIN USE WITH RISK OF NEWLY ONSET NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DEVELOPMENT. Retina. 2024 02 01; 44(2):205-213.
-
Transcriptomic signatures of individual cell types in cerebral cavernous malformation. Cell Commun Signal. 2024 01 09; 22(1):23.
-
Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial. JAMA Ophthalmol. 2023 Dec 01; 141(12):1152-1160.
-
Oral Metformin Inhibits Choroidal Neovascularization by Modulating the Gut-Retina Axis. Invest Ophthalmol Vis Sci. 2023 Dec 01; 64(15):21.